A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Pilot study to evaluate the ability of BR55 to identify prostate cancer lesions with Gleason
Score ≥7 by ultrasound molecular imaging on the basis of a visual score in comparison with
histopathology results